Multiple Myeloma (MM) remains an incurable disease. Scientific understanding of the biology and influence
of the microenvironment in disease progression and outcome has led to treatment improvements by targeting angiogenesis.
Reviews of the underlying biology and meta-analyses of the clinical data tend to be mutually exclusive. This minireview
highlights important data regarding angiogenesis in MM as well as the drugs currently used to target angiogenesis
in its treatment.
Keywords: Angiogenesis inhibitors, anti angiogenetic agents, anti-angiogenic effects, immunomodulation, multiple myeloma.
Rights & PermissionsPrintExport